QQ客服 官方微博 反馈留言

	The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
	Xing, Puyuan; Zhu, Yixiang; Shan, Ling; Chen, Sipeng; Hao, Xuezhi; Li, Junling
刊名	ONCOTARGET
	2017
卷号	8期号:50
关键词	advanced non-small cell lung cancer (NSCLC) multiple treatments taxane nanoparticle albumin bound paclitaxel (Nab-PTX) secreted protein acidic and rich in cysteine (SPARC)
ISSN号	1949-2553
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3612441
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Xing, Puyuan,Zhu, Yixiang,Shan, Ling,et al. The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China[J]. ONCOTARGET,2017,8(50).
APA	Xing, Puyuan,Zhu, Yixiang,Shan, Ling,Chen, Sipeng,Hao, Xuezhi,&Li, Junling.(2017).The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.ONCOTARGET,8(50).
MLA	Xing, Puyuan,et al."The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China".ONCOTARGET 8.50(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。